Cationic liposome-mediated RNA transfection.

Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46

Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A (2010) 4.25

Mutational analysis of the conserved motifs of influenza A virus polymerase basic protein 1. J Virol (1994) 2.98

Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J Virol (1993) 2.39

Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A (1992) 2.30

Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A (1996) 2.19

Lipid-based nanotherapeutics for siRNA delivery. J Intern Med (2010) 2.15

In vivo analysis of the promoter structure of the influenza virus RNA genome using a transfection system with an engineered RNA. Proc Natl Acad Sci U S A (1991) 2.03

Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A (2012) 1.90

Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87

trans-dominant inhibition of human hepatitis delta virus genome replication. J Virol (1991) 1.79

Suppression of ischemia-induced fos expression and AP-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA. Ann Neurol (1994) 1.69

A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A (1996) 1.44

Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res (2001) 1.38

Effect of vesicular stomatitis virus matrix protein on host-directed translation in vivo. J Virol (1994) 1.34

Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24

Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum Gene Ther (2013) 1.21

Direct introduction and transient expression of capped and non-capped RNA in Saccharomyces cerevisiae. Nucleic Acids Res (1991) 1.20

A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res (1995) 1.20

In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm (2011) 1.17

Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharm (2010) 1.17

Liposomes for use in gene delivery. J Drug Deliv (2010) 1.15

Delta ribozyme benefits from a good stability in vitro that becomes outstanding in vivo. RNA (2002) 1.13

Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. PLoS One (2010) 1.13

Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun (2015) 1.13

RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest (2000) 1.12

Import of amber and ochre suppressor tRNAs into mammalian cells: a general approach to site-specific insertion of amino acid analogues into proteins. Proc Natl Acad Sci U S A (2001) 1.11

Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol (1994) 1.08

Antimycobacterial agent based on mRNA encoding human beta-defensin 2 enables primary macrophages to restrict growth of Mycobacterium tuberculosis. Infect Immun (2001) 1.08

Terminal 7-methyl-guanosine cap structure on the normally uncapped 5' noncoding region of poliovirus mRNA inhibits its translation in mammalian cells. J Virol (1991) 1.07

Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res (2002) 1.05

Developing mRNA-vaccine technologies. RNA Biol (2012) 1.04

RNA processing and ribonucleoprotein assembly studied in vivo by RNA transfection. Proc Natl Acad Sci U S A (1990) 1.03

Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells. Mol Cell Biol (1994) 0.96

Highly efficient paramagnetic labelling of embryonic and neuronal stem cells. Eur J Nucl Med Mol Imaging (2003) 0.96

Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug Chem (2011) 0.92

Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol (2012) 0.91

Antioxidant enzyme gene transfer for ischemic diseases. Adv Drug Deliv Rev (2009) 0.90

In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One (2013) 0.90

Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects. Nat Commun (2016) 0.89

Vectorology and factor delivery in induced pluripotent stem cell reprogramming. Stem Cells Dev (2014) 0.88

Biomaterials for mRNA delivery. Biomater Sci (2015) 0.87

RNA vaccines in cancer treatment. J Biomed Biotechnol (2010) 0.87

Future of the particle replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed Engl (2013) 0.86

Protective role for proteoglycans against cationic lipid cytotoxicity allowing optimal transfection efficiency in vitro. Biochem J (1999) 0.86

Lipid-modified aminoglycoside derivatives for in vivo siRNA delivery. Adv Mater (2013) 0.86

A Simple, Highly Efficient Method for Heterologous Expression in Mammalian Primary Neurons Using Cationic Lipid-mediated mRNA Transfection. Front Neurosci (2010) 0.84

RNA replicon delivery via lipid-complexed PRINT protein particles. Mol Pharm (2013) 0.83

Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81

Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse. PLoS One (2007) 0.81

A method for stabilizing RNA for transfection that allows control of expression duration. Dev Dyn (2010) 0.81

Microinjection free delivery of miRNA inhibitor into zygotes. Sci Rep (2014) 0.80

Surfactant-mediated gene transfer for animal cells. Cytotechnology (1997) 0.80

Viral and Synthetic RNA Vector Technologies and Applications. Mol Ther (2016) 0.80

Structure-Based Design of Dendritic Peptide Bolaamphiphiles for siRNA Delivery. ACS Cent Sci (2015) 0.80

RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res (2015) 0.78

Inhibition of Xenograft tumor growth by gold nanoparticle-DNA oligonucleotide conjugates-assisted delivery of BAX mRNA. PLoS One (2013) 0.78

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother (2014) 0.78

Fighting against kidney diseases with small interfering RNA: opportunities and challenges. J Transl Med (2015) 0.78

Multi-level kinetic model of mRNA delivery via transfection of lipoplexes. PLoS One (2014) 0.77

Lipid nanoparticles for gene delivery. Adv Genet (2014) 0.76

Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver. Gene Ther (2015) 0.76

Cytoplasmic expression systems triggered by mRNA yield increased gene expression in post-mitotic neurons. Nucleic Acids Res (2006) 0.76

Perspectives on cell reprogramming with RNA. Trends Biotechnol (2012) 0.76

Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther (2015) 0.75

Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther (2017) 0.75

Antibacterial, cytotoxic and genotoxic activity of nitrogenated and haloid derivatives of C50-C60 and C70-C120 polyprenol homologs. Lipids Health Dis (2016) 0.75

Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials (Basel) (2016) 0.75

Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression. Sci Rep (2015) 0.75

Vesicle fusion with bilayer lipid membrane controlled by electrostatic interaction. Biochem Biophys Rep (2017) 0.75

In vitro studies of liposome-mediated gene transfer into head and neck cancer cell lines. Eur Arch Otorhinolaryngol (1997) 0.75

Focused Library Approach to Discover Discrete Dipeptide Bolaamphiphiles for siRNA Delivery. Biomacromolecules (2016) 0.75

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81

Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol (1986) 55.34

Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol (1987) 26.70

Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J Mol Biol (1983) 19.98

Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A (1987) 18.91

Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res (1984) 14.92

Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 8.59

Covalent linkage of a protein to a defined nucleotide sequence at the 5'-terminus of virion and replicative intermediate RNAs of poliovirus. Proc Natl Acad Sci U S A (1977) 8.12

5'-terminal cap structure in eucaryotic messenger ribonucleic acids. Microbiol Rev (1980) 6.14

Multicomponent RNA plant virus infection derived from cloned viral cDNA. Proc Natl Acad Sci U S A (1984) 4.70

Poly(A) shortening and degradation of the 3' A+U-rich sequences of human c-myc mRNA in a cell-free system. Mol Cell Biol (1988) 3.96

In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14. J Virol (1985) 3.19

Effect of 5'-terminal structure and base composition on polyribonucleotide binding to ribosomes. J Mol Biol (1976) 1.84

5'-Terminal 7-methylguanosine and mRNA function: influence of potassium concentration on translation in vitro. Proc Natl Acad Sci U S A (1977) 1.35

Importance of initiation factor preparations in the translation of reovirus and globin mRNAs lacking a 5'-terminal 7-methylguanosine. J Biol Chem (1977) 1.34

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95

Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23

Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39

Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15

Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. Nature (1985) 8.36

Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol (1985) 7.49

The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol (1996) 6.62

Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60

Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science (1999) 6.20

FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol (1982) 6.11

Gene therapy -- promises, problems and prospects. Nature (1997) 6.02

Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell (1983) 5.79

Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell (1990) 5.59

c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell (1984) 5.55

Nucleotide sequence of the genome of a murine sarcoma virus. Cell (1981) 5.48

Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature (1988) 5.18

Viral and cellular fos proteins: a comparative analysis. Cell (1984) 4.89

Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor. Science (1984) 4.87

Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature (1986) 4.70

Expression of cellular oncogenes in human malignancies. Science (1984) 4.48

Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature (1982) 4.44

Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci U S A (1983) 4.38

Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet (1997) 4.26

The reverse transcriptase. Biochim Biophys Acta (1977) 4.16

Transcriptional autoregulation of the proto-oncogene fos. Nature (1988) 4.10

Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06

Nucleotide sequence and formation of the transforming gene of a mouse sarcoma virus. Nature (1981) 4.05

In vitro synthesis of DNA complementary to rabbit reticulocyte 10S RNA. Nat New Biol (1972) 4.01

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A (1995) 3.90

fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell (1988) 3.82

Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell (1985) 3.81

Transcriptional activation by BRCA1. Nature (1996) 3.64

Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell (1992) 3.55

Structure of Moloney murine leukemia viral DNA: nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. Proc Natl Acad Sci U S A (1980) 3.53

The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev (1991) 3.52

Direct interaction between fos and jun nuclear oncoproteins: role of the 'leucine zipper' domain. Nature (1988) 3.43

Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem (1994) 3.41

Analysis of the env gene of a molecularly cloned and biologically active Moloney mink cell focus-forming proviral DNA. J Virol (1982) 3.40

Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A (1997) 3.40

Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37

Studies on reverse transcriptase of RNA tumor viruses III. Properties of purified Moloney murine leukemia virus DNA polymerase and associated RNase H. J Virol (1975) 3.31

A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci U S A (1983) 3.31

Covalently linked RNA-DNA molecule as initial product of RNA tumour virus DNA polymerase. Nat New Biol (1971) 3.27

I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell (1992) 3.25

c-fos promoter trans-activation by the tax1 protein of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1988) 3.24

Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A (1994) 3.24

Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A (2001) 3.24

Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 3.10

Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMLV-1). J Virol (1984) 3.09

Removal of a 67-base-pair sequence in the noncoding region of protooncogene fos converts it to a transforming gene. Proc Natl Acad Sci U S A (1985) 2.95

Regulated mRNA stability. Annu Rev Genet (1990) 2.93

IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev (1999) 2.92

Nucleotide sequence of Moloney leukemia virus: 3' end reveals details of replications, analogy to bacterial transposons, and an unexpected gene. Proc Natl Acad Sci U S A (1980) 2.90

Viral and cellular fos proteins are complexed with a 39,000-dalton cellular protein. Mol Cell Biol (1985) 2.86

Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A (1991) 2.85

Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol (1990) 2.82

Heteroduplex analysis of the sequence relations between the RNAs of mink cell focus-inducing and murine leukemia viruses. J Virol (1978) 2.79

Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science (1984) 2.75

Induction of the proto-oncogene fos by nerve growth factor. Proc Natl Acad Sci U S A (1985) 2.74

M-MuLV-induced leukemogenesis: integration and structure of recombinant proviruses in tumors. Cell (1981) 2.65

c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A (1991) 2.65

Gene therapy: trials and tribulations. Nat Rev Genet (2000) 2.62

Studies on the reverse transcriptase of RNA tumor viruses. Structural relatedness of two subunits of avian RNA tumor viruses. Proc Natl Acad Sci U S A (1974) 2.60

Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol Cell Biol (1983) 2.53

Expression of a retrovirus encoding human HPRT in mice. Science (1984) 2.48

Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A (2001) 2.48

The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol (1990) 2.47

Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol Cell Biol (1987) 2.40

Identification of a transcriptional enhancer element upstream from the proto-oncogene fos. Science (1985) 2.39

Induction of proto-oncogene fos transcription through the adenylate cyclase pathway: characterization of a cAMP-responsive element. Genes Dev (1988) 2.38

mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol Cell Biol (1990) 2.38

Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A (1991) 2.34

Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A (1992) 2.30

Direct association of pp40/I kappa B beta with rel/NF-kappa B transcription factors: role of ankyrin repeats in the inhibition of DNA binding activity. Proc Natl Acad Sci U S A (1992) 2.29

Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. Cell (1982) 2.27

A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22

Identification of a RNA polymerase II initiation site in the long terminal repeat of Moloney murine leukemia viral DNA. Proc Natl Acad Sci U S A (1981) 2.16

Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14

Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci U S A (1994) 2.12

Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther (2000) 2.12

Both the basic region and the 'leucine zipper' domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation. EMBO J (1990) 2.11

Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambda. J Virol (1980) 2.10

Role of Rel/NF-kappaB transcription factors during the outgrowth of the vertebrate limb. Nature (1998) 2.08

Expression of c-onc genes: c-fos transcripts accumulate to high levels during development of mouse placenta, yolk sac and amnion. EMBO J (1983) 2.08

Fos-Jun interaction: mutational analysis of the leucine zipper domain of both proteins. Genes Dev (1989) 2.06

Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol (2000) 2.04

BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A (1997) 2.02

Identification and molecular cloning of Moloney mouse sarcoma virus-specific sequences from uninfected mouse cells. Proc Natl Acad Sci U S A (1980) 1.98

Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev (2000) 1.96

Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B. Nature (1993) 1.94

Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A (1999) 1.90

Size analysis and relationship of murine leukemia virus-specific mRNA's: evidence for transposition of sequences during synthesis and processing of subgenomic mRNA. J Virol (1978) 1.90

DNA polymerase activity from two temperature-sensitive mutants of Rous sarcoma virus is thermolabile. Nature (1974) 1.90

Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc Natl Acad Sci U S A (1994) 1.89

c-fos expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages. Cell (1986) 1.87

Thermolabile reverse transcriptase of a mammalian leukemia virus mutant temperature sensitive in its replication and sarcoma virus helper functions. J Virol (1975) 1.87

Studies on reverse transcriptase of RNA tumor viruses. I. Localization of thermolabile DNA polymerase and RNase H activities on one polypeptide. J Virol (1975) 1.84

Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol (1998) 1.84

Rel/NF-kappa B/I kappa B story. Adv Cancer Res (1995) 1.83